English
Chinese
Cart
This product is not clubbable with other items in cart. Please remove this or other items to proceed further.
Deleting
No Items In Cart
NovaPure® Stoppers
Overview
Product Attributes
NovaPure components can be supplied washed (ready to sterilize) or sterilized (ready to use) in standard STERIlizableBAG™ packaging or in ported bags depending on your need. To find out more about our sterile small quantity offerings, you can also refer to West Ready Pack® brand offering.
Packaging Options
Downloadable Resources
Related Products
Other Offerings
Daikyo® Crystal Zenith® is a registered trademark of Daikyo Seiko, Ltd.
Daikyo® Crystal Zenith® technology is a registered trademark of Daikyo Seiko, Ltd.
NovaPure, FluroTec and Ready Pack are registered trademark of West Pharmaceutical Services, Inc., in the United States and other jurisdictions.
Daikyo® Crystal Zenith® and FluroTec® technology are licensed from Daikyo Seiko, Ltd.
Daikyo® Crystal Zenith® technology is a registered trademark of Daikyo Seiko, Ltd.
NovaPure, FluroTec and Ready Pack are registered trademark of West Pharmaceutical Services, Inc., in the United States and other jurisdictions.
Daikyo® Crystal Zenith® and FluroTec® technology are licensed from Daikyo Seiko, Ltd.
Related Blogs
April 02, 2021
FluroTec™ Barrier Films – Protecting Your Biologics
There is no doubt biologics and biosimilars will remain one of the hot topics in 2021. This is due to the pandemic period of SARS-CoV-2 and the innovative treatments and vaccines that are under development at accelerated speed. Several questions can arise regarding selection of the proper primary package system for a biologic/biosimilar.
August 19, 2020
How are you responding to pharmacopoeia expectation of parenteral preparations?
Regulatory agencies are driving the pharmaceutical industry to continuously improve the quality of drug products, but what is the reality for a drug developer who is expected to make parenteral preparations “practically free from particles”? Expectations of packaging are changing fast but how well prepared is the packaging to meet these needs?
March 16, 2021
Addressing the Challenges in Research for Biologics
In recent years, an increasing variety of biologic drugs have been developed including vaccines, recombinant proteins, gene and cell therapies. In China, this increased demand will be reflected in a significant growth in the size of the bio-pharmaceutical industry. As a result, the Chinese government is increasing its investment.
April 02, 2021
FluroTec™ Barrier Films – Protecting Your Biologics
There is no doubt biologics and biosimilars will remain one of the hot topics in 2021. This is due to the pandemic period of SARS-CoV-2 and the innovative treatments and vaccines that are under development at accelerated speed. Several questions can arise regarding selection of the proper primary package system for a biologic/biosimilar.
August 19, 2020
How are you responding to pharmacopoeia expectation of parenteral preparations?
Regulatory agencies are driving the pharmaceutical industry to continuously improve the quality of drug products, but what is the reality for a drug developer who is expected to make parenteral preparations “practically free from particles”? Expectations of packaging are changing fast but how well prepared is the packaging to meet these needs?
March 16, 2021
Addressing the Challenges in Research for Biologics
In recent years, an increasing variety of biologic drugs have been developed including vaccines, recombinant proteins, gene and cell therapies. In China, this increased demand will be reflected in a significant growth in the size of the bio-pharmaceutical industry. As a result, the Chinese government is increasing its investment.
